(Erstwhile PGA Labs) Report April 2023 Molecular diagnostics as a modality where molecular diagnostics will play Foreword of IVD got a tremendous boost more and more role in the future. during the pandemic with even There is growing interest in molecular common people getting acquainted diagnostics market from investors like with the term RT-PCR. Molecular the recent investment of US$ 85 diagnostics is here to stay, with Million by Temasek in Molbio distinct advantages of high level of Diagnostics, from corporates like accuracy and early detection of Reliance Industries and Tata group infection, being highly sensitive to and also from a host of startups like lower amounts of infectious agents. D-nome, Swagene. Medgenome etc. I Though the current level of adoption am sure our report on the molecular Arindam Gupta is still quite low, the molecular diagnostics market in India will Executive Vice President diagnostics market in India is provide key insights to both the IVD Healthcare & Life Sciences 1Lattice expected to be about US$1.6 Billion companies and diagnostics service by 2030. While current applications providers, expanding to molecular of molecular diagnostics are already diagnostics. Overal, molecular into some aspects of Oncology and diagnostics is going to play an Infectious Diseases, there are important role in improving patient emerging applications in genetics, outcome with predictive medicine, hematopathology, cardiovascular early diagnosis and the ability to diseases and neurological diseases. monitor the efficacy of treatment Perinatal screening and predictive modalities. testing are two important areas Executive Summary Molecular diagnostics - overview • The Indian molecular diagnostics market valued at ~US$ 0.95B in 2022 is expected to grow at CAGR of ~7% to ~US$ 1.6B by 2030 whereas the global molecular diagnostics market is projected to grow at a CAGR of ~5% during the same period Existing areas • The current application areas of molecular diagnostics include oncology and infectious diseases • In oncology, predictive testing is presently being conducted for cancers like breast, ovarian, endocrine, lynch syndrome, pancreatic, blood, renal cancers etc. • Molecular diagnostics provide reliable diagnosis for communicable infectious diseases like covid-19, dengue, malaria, tuberculosis, influenza, HIV and hepatitis Emerging areas • Emerging application areas of molecular diagnostics include genetics, hematopathology, cardiovascular diseases and neurological diseases • Molecular diagnostics facilitates predictive testing by detecting mutations associated with disorders that may appear later in life and guides therapeutic approaches by predicting how certain drugs will affect the body based on gene mutations Popular techniques • PCR is currently the most popular technique in molecular diagnostics followed by isothermal amplification, nucleic acid hybridization, and microarrays • PCR segment dominated the infectious disease molecular diagnostics market & accounted for ~90% revenue in 2020 Top players and market segmentation • Global diagnostics market is dominated by players like Roche and Abbott • Besides Covid-19 reagents, TB reagents had the highest share in the Indian molecular diagnostics reagent market in 2021 © 1lattice | 03 Executive Summary Impact of COVID - 19 • No. of testing labs has increased from 14 in February 2020 to 106 VRDLs in March 2022. India currently has 3000+ molecular testing laboratories • 14 Centers of Excellence were set up in April 2020 to create a molecular virology lab network • There has been an increase in investments in molecular diagnostics startups in India Growth drivers & barriers • There have been rapid technological advancements to obtain low-cost, & highly portable & accurate products • PCR market has grown due to rising prevalence of diseases & genetic disorders such as Sickle cell Anemia & Cystic Fibrosis • High costs, lack of trained professionals, low penetration, and disruptions in transportation and power supply are some of the factors hindering the growth of molecular diagnostics market in India. Competitive landscape • Local players like Molbio, Mylab and TATA MD are striving to make their place in the Indian molecular diagnostics market. Some startups have also raised investments in recent years Popular techniques • The purchase journey of the equipment involves sales pitch, research, trial tests, management approval and installation & purchase agreement • The type of system (closed / open), accuracy, cost and quality of the product are some of the major factors affecting the purchase decision © 1lattice | 04 Overview Molecular Diagnostics at a glance Current Application Areas Molecular pathology or molecular diagnostics refers to the set of techniques that involves sequencing the genetic material (DNA or RNA) to detect and analyse the genetic mutations associated with diagnosis of current disease and prediction of Oncology Infectious Diseases future disease. • Breast cancer • Hepatitis The Indian molecular diagnostics market is expected to grow at CAGR of ~7% from • Cervical cancer • HIV ~US$ 0.95B in 2022 to ~US$ 1.6B in 2030. • Renal cancer • Coronavirus • Pancreatic cancer • HPV • Endocrine Cancer • Tuberculosis Indian Molecular Diagnostics Market size • Influenza (in US$ B) The Indian molecular diagnostics market Post Covid-19, the Growth witnessed massive CAGR Indian molecular rate growth during the 7% diagnostics market 33% Covid-19 pandemic Major highlights will grow at a normalised CAGR of ~7% from 2022-2030 The molecular diagnostics market is estimated to have ~10% share of the overall diagnostics market in India in the CY2021 1.6 The global molecular diagnostics market is projected to grow 1.2 at a CAGR of ~5% from 2022-2030 0.95 0.9 Adoption rate of molecular diagnostics is likely to see high growth in Asia-Pacific markets in the coming years Reagents and kits are likely to drive the growth of the global 2020E 2021E 2022E 2030P molecular diagnostics market Source(s): Grand View Research, Mordor Intelligence, 1Lattice analysis © 1lattice | 05 Existing areas Oncology and infectious diseases are the most popular current areas of application of molecular diagnostics Benefits Oncology Infectious Diseases • Molecular diagnostics enables early • Molecular testing provides fast and accurate Reliable detection of cancer-predisposing mutations results due to their sensitive nature. diagnosis to identify hereditary cancer syndromes Quantitative tests enable effective treatment management by assessing the severity of the • Predictive testing is presently being infection from time to time conducted for cancers like breast, ovarian, endocrine, lynch syndrome, pancreatic, • The most common communicable infectious blood, renal cancers etc. Early detection diseases are covid-19, dengue, malaria, Predictive Monitoring enables preventive medical intervention tuberculosis, influenza and hepatitis testing of treatment • Targeted therapy for solid cancers like lung, • Tuberculosis, HIV, and chronic hepatitis are colon, prostate etc can be conducted as it among the most common life-threatening facilitates personalisation of treatment based infectious diseases in India on presence of actionable mutations Total no. of cancer cases are The incidence of breast The total no. of cases of HIV, The incidence rate of HIV estimated to grow at rate of cancer in women was 205K tuberculosis stood at ~25L was reported to be 0.05 per ~2% from 2020-2025 in 2020 and ~20L respectively in 2021 1000 uninfected population Key in 2021 by NACO Statistics The oncology diagnosis The incidence of lung As per WHO, around 40M and 12M people are chronically procedures are projected to cancer in men was 72K in infected with Hepatitis B and C virus in India increase at rate of ~15% by 2020 2025 Source(s): World Health Organisation website, Press Information Bureau, National AIDS Control Organisation (NACO), 1Lattice analysis © 1lattice | 06 Emerging areas Emerging application areas of molecular diagnostics Genetics ▪ Molecular diagnostics facilitates predictive testing by detecting mutations associated with disorders that may appear later in life ▪ It guides therapeutic approaches for these disorders by predicting how certain drugs will affect the body based on gene mutations ▪ Genetic testing can also be applied to new-born screening, prenatal screening, etc ▪ Thalassemia, cystic fibrosis, sickle cell anaemia, spinal muscular atrophy and haemophilia are the most common genetic disorders Hematopathology ▪ Technological advancements in molecular biology has paved the way for development of personalised diagnostics and treatment of haematological disorders ▪ Few popular molecular diagnostic techniques in the filed of hematopathology include PCR, fluorescence in situ hybridization (nucleic acid hybridization) etc ▪ Anaemia, thalassemia, and haemophilia are the most common blood disorders Cardiovascular Disease ▪ Recent advances in molecular genetic testing have revealed that gene aberrations may have direct or indirect effects on cardiovascular diseases ▪ Enables rapid & reliable detection of gene defects that benefits drug therapy and genetic counselling for effective treatment ▪ Coronary heart disease, congenital heart disease, rheumatic heart disease, cardiac arrhythmia, cardiomyopathy, heart failure, etc. are the most common cardiovascular diseases Neurological Diseases ▪ Molecular diagnostics is expected to play an imperative role in diagnosis of neurological disorders at an early stage ▪ Epilepsy, Cerebrovascular accident, Parkinson's disease, Alzheimer’s are common neurological disorders among Indians Source(s): Primary research, Secondary research, 1Lattice analysis © 1lattice | 07 Techniques PCR segment dominated the infectious disease molecular diagnostics market & accounted for ~90% revenue in 2020 Popular Techniques 1 2 3 4 PCR (Polymerase Chain Isothermal Amplification: Nucleic Acid Hybridization: It Microarrays (DNA Chip): Reaction): PCR has been the most Another popular testing technique involves bonding of two Microarrays are slides with tiny popular technology used for is Isothermal Amplification. Unlike single-stranded DNA and/or RNA spots in well-defined positions molecular testing. It helps in PCR, this method does the into a double-stranded molecule that carry a specific DNA detecting the if a target genetic amplification without temperature to identify a particular genetic sequence or gene. It helps in sequence of DNA or RNA is changing cycles and rather uses sequence. detecting the gene mutations that present by amplifying it to enzymic characteristics to carry cause a particular disease by noticeable levels. It is far more out the process. It is less popular analysing the genetic expression sensitive and specific as compared than PCR because of its expensive of the biomolecule. conventional tests. nature The PCR segment dominated the market for infectious disease molecular diagnostics and accounted for the largest revenue share of 90.4% in 2020. Popularity Very low Very high Source(s): Primary research, Secondary research, 1Lattice analysis © 1lattice | 08 Top players Global diagnostics market is dominated by players like Roche and Abbott Diagnostics Type of products Year Type of Company He adquarters Brief description segment revenue Established system Equipment Reagent (2021) Developer of drugs and diagnostic kits for multiple Swit ze rland 1896 ~US$ 18B Closed diseases Developer of medical devices, pharmaceuticals & USA 1888 ~US$ 15.5B Closed nutrition products Manufacturer of scientific instruments, USA ~US$ 6B Open 1956 consumables, and chemicals Developer of diagnostic and clinical systems and Germany ~US$ 5.5B Open 1896 solutions USA 1897 Developer of diagnostic solutions and life sciences ~US$ 5B Open United Kingdom 1985 Provider of diagnostic and surgical products ~US$ 2B Closed Netherlands ~US$ 2B Open 1984 Provider of sample and assay technologies Developer of innovative products for the life USA ~US$ 1.5B Open 1952 science research and clinical diagnostic markets Developer of diversified instruments for scientific USA 1999 ~US$ 1.3B Open and laboratory management USA 1996 Developer of molecular diagnostics testing solutions ~US$ 0.5B Closed Developer of molecular diagnostics instruments India ~US$ 0.16B Closed 2000 and reagents India 2016 Developer of diagnostic kits and assays ~US$ 0.1B Open India 2011 Developer of diagnostic testing solutions ~US$ 0.03B - Source(s): Primary research, Secondary research, 1Lattice analysis © 1lattice | 09 Market segmentation TB reagents had the highest share in molecular diagnostics reagent market in 2021 I ndian Molecular D iagnostics Reagents Segment L eading Players Market (2021) (US$ ~34M) TB Reagents 9% 3% 5% HIV, HCV, HBV 43% Oncology Reagents 40% H1N1 Reagents Other infectious diseases H1N1 Other infectious Diseases (HPV, dengue, Oncology HIV, HCV,HBV STI markers) TB Note(s): The above market size is exclusive of Covid – 19 reagents Source(s): ADI Media Research, 1Lattice Analysis © 1lattice | 10 Prices Various applications of PCR technique in the oncology segment Average test pricing Test Other non-molecular Test function / Cancer Requirement (in US$) classi fi cation tests Mutation JAK2 ,BCR-ABL, MPN, PML Blood cancer Rara, AML, NRAS, BRAF KRAS, ~60-130 Risk assessment Screening & Monitoring Tumor marker t est CALR, AML/ETO, FLT-3 Cancer antigens 15-3, OncoBRCA-Next,BRCA1 & Breast cancer ~240-300 Risk assessment Screening & Monitoring Breast cancer marker test, BRCA2 Comprehensive panel Tumour marker test Optional PAP smear test, HPV DNA testing ~25-60 Liquid cytology recommendation Cervical cancer Screening & Diagnosis HPV Genotyping ~20-35 Risk assessment - Epidermal growth factor ~70-120 Risk assessment Screening & Monitoring recepto r (EGFR) L ung cancer Cyfra 21 (Lung cancer marker) Lung cancer genomic ~300-360 High risk assesment Screening & Monitoring sequencing Multiple cancer - Kras mutation CODON Carcinoembryonic antigen ~90-95 Risk assessment Screening & Monitoring L ung, Colorectal, 12 & 13 test Pancreatic Fecal occult blood test, Optional Microsatellite instability Carcinoembryonic antigen Colorectal cancer ~170-190 Screening & Monitoring recommendation (MSI) test Note(s): The above market size is exclusive of Covid – 19 reagents Source(s): ADI Media Research, 1Lattice Analysis © 1lattice | 11 Prices Various applications of PCR technique in the infectious diseases segment Average test Pricing Other non-molecular Diseases Test Test Classification Requirement (in US$) tests Influenza A virus (IgG), Influenza H1N1 / Swine Flu RT PCR ~50-60 Optional recommendation Diagnosis ELISA (SR) test MTB PCR ~25-35 Optional recommendation Tuberculosis Diagnosis & Monitoring TB ELISA test Qualitative ~60-65 Optional recommendation Diagnosis HIV rapid card test HIV Viral load ~65-95 Core recommendation Monitoring - Qualitative ~35-50 Optional recommendation Diagnosis Rapid card test HBsAg HBV Viral load ~55-60 Core recommendation Diagnosis & Monitoring - Qualitative ~25-50 Optional recommendation Diagnosis Rapid card test HCV HCV Viral load ~50-85 Core recommendation Diagnosis & Monitoring - SARS - CoV - 2 IgG SARS-CoV-2 PCR ~3-6 Core recommendation Covid-19 Diagnosis Antibody test Dengue RNA Qualitative ~25-50 Optional recommendation Diagnosis Dengue fever panel (ELISA) Dengue This test is not used to Chikungunya Chikungunya PCR ~20-25 Optional recommendation Diagnosis Chikungunya IgM diagnose active or Leptospira Leptospira DNA PCR ~25-30 Optional recommendation Diagnosis Leptospira IgM recent infection. Herpes simplex virus Herpes Herpes simplex virus DNA PCR ~50-60 Optional recommendation Diagnosis 1+2 IgG Ab serum Note(s): Average test pricing is indicative of only molecular test Source(s): ADI Media Research, 1Lattice Analysis © 1lattice | 12 Impact of COVID-19 The need for rapid & accurate diagnosis during the COVID-19 pandemic augmented the adoption of molecular diagnostics in the Indian healthcare system Effect of COVID-19 on Market attractiveness Description molecular testing capacity 1 • Increase in no. of testing labs from 14 in February 2020 to Increase in Increase in • WHO recommends use of rapid molecular 106 VRDLs in March 2020 COVID-19 fatal & chronic diagnostic tools for diagnosis of TB testing capacity • Currently India has 3000+ molecular testing laboratories disease cases • Molecular diagnostic startup D-NOME 2 Mentor raised investment from Ankur capital • 14 Centers of Excellence were set up in April 2020 to institutes for • Molbio diagnostics received US$ 85M Increase in create a molecular virology lab network upscaling testing investment from Temasek investments • Rivaara Labs raised US$ 7.3M by Amicus 3 Capital & Kotak Investment Advisors Augmenting • Out of 540 Medical colleges in the country, 293 have VRDLs in medical set up molecular virology labs • InDX aims is to lower the cost of RT-PCR to colleges increase affordability 4 • The Ministry of Health and Family welfare Robust supply • Online IMS rolled out at the lab level for robust projections launched Prevention and Control of chain process and timely procurement to meet testing needs Government Hemoglobinopathies Program in 2016 Initiatives under which it aims to control two major 5 Collaborating hemoglobinopathies - thalassemia and with private sickle cell disease through molecular • 250 labs were registered with NABL for various scopes, sector to boost testing and prenatal diagnosis for 400+ private sector labs selected for testing testing capacity screening and treatment 6 • ICMR engaged with MoHFW labs, CSIR, DBT, DRDO, ICAR, • Growth drivers include access to easy POC molecular Increased gov. medical colleges & private labs to intensify testing home tests, growing use of RT-PCR in diagnostic accessibility in • Mapping of remote areas to cover underserved areas like proteomics, genomics, & COVID-19 testing Market remote areas Ladakh, Sikkim, Tripura, Mizoram, Lakshadweep etc. Note(s): IMS- Inventory management system; VRDLs – Virus Research & Diagnostic Laboratories Source(s): Secondary research, 1Lattice analysis © 1lattice | 13 Growth drivers Rising focus on R&D, demand for POC diagnostics and COVID-19 impact is providing growth opportunities in molecular diagnostics market in India Technological Advancements Augmented Applications Rapid technological advancements to obtain PCR market has grown due to rising prevalence of low-cost, & highly portable & accurate products diseases & genetic disorders such as Sickle cell Anemia & Cystic Fibrosis, coupled with increased New set of Molecular diagnostic tools are being recognition of PCR as the best method for developed for tumor diagnosis by Sigma Aldrich amplifying DNA sequences Corporation & QIAGEN such as - Transcription-Mediated Amplification (TMA) Rising Income Levels and Health Awareness and Loop-Mediated Isothermal Amplification (LAMP) The proportion of households earning more than Growth Covid–19 Impact ~US$ 2.5K has risen from 23% in FY17 to 35% in Drivers FY22 Increase in no. of testing labs from 14 in February Increase in literacy rates, disposable incomes, & 2020 to 106 Virus Research & Diagnostic rapid urbanization, has led to higher standards and Laboratories in March 2020 anchored COVID-19 more awareness regarding the availability and diagnosis in the country accessibility of diagnostic tests for both preventive ~3000 labs currently perform molecular testing and curative care in India Rising Geriatric Population Demand for Point of Care (PoC) diagnostics Geriatric population is expected to rise 41% in the Market has witnessed major shift towards precision next decade medicine, population health, & chronic disease Growing prevalence of chronic diseases such as management Hypertension, Arthritis, TB etc. in geriatric PoC tech provides operative data to facilitate quick population with weak immune system is considered clinical judgement as a primary demand driver for diagnostics Note(s); US$ 1= INR 81.5 Source(s): Secondary research, 1Lattice analysis © 1lattice | 14 Growth drivers High costs and lack of access to advanced medical technologies in remote areas are the main factors limiting the growth of molecular diagnostics Scarcity / Lack of Disruptions in High cost of Considerable Lack of penetration trained and skilled transportation and molecular diagnostics operating costs in rural areas pathologists power supply 1 2 3 4 5 • Based on NSSO • According to the • Substantial • Urban areas account • Importation of survey ~7% of India’s Indian Association of functioning costs for ~75% of the reagents causes population is pushed Pathologists & associated with whole market with supply chain into poverty every Microbiologists there effective restricted disruptions year due to are ~4,500 members instrumentation, penetration in tier 3 • Molecular laboratories healthcare expenses in India sample acquirement, / 4 / 5 cities require constant • Lack of funds & high • Because of lack of storage and • Use of outdated & supply of power to cost of molecular training programs, transportation inefficient prevent disruptions in diagnostics is career development • Lab spaces also need technologies in rural testing and provide expected to hinder opportunities & to be reconstructed to areas lead to wrong proper storage for the growth of the sufficient protective avoid diagnoses & poor samples market gear there is a severe cross-contamination treatment outcomes shortage of skilled and ensure time pathologists & management for technicians certain molecular diagnostic tests Sources: Secondary research, 1Lattice analysis © 1lattice | 15 Competitive landscape The Indian healthcare market has witnessed the emergence of many local players in the molecular diagnostics segment in recent years For instruments & reagents Recent developments • Hyderabad-based molecular diagnostics start-up D-nome raised investment International Players from Ankur Capital in 2022. • Genetic Analysis, a molecular diagnostic specialist, partnered with Mumbai based, Microbiome Research Pvt. Ltd to launch GA-map technology in India in 2022 • The Tata Medical and Diagnostics is an emerging player in the molecular diagnostics market. It is developing molecular diagnostic solutions for infectious diseases and cancer • Reliance Industries plans to roll-out a comprehensive and affordable genome sequencing kit, developed by Strand Life Sciences National Players Most of the startups that have emerged in this space in recent years aim to address issues like affordability and requirement of skilled manpower, etc. that are currently being faced in Tier II and Tier III cities with respect Trupcr, Solution one and to PoC diagnostics. Some of these startups are also working towards Angstrom are only manufacturing reagents leveraging artificial intelligence to achieve reliable and effective therapeutic and diagnostic applications - Dr. Rajesh Srinivasan, Scientist at IISc Closed system Source(s): Company websites, Secondary research, 1Lattice analysis © 1lattice | 16 Purchase journey - key considerations of GTM The type of system (open / closed) is a major factor influencing the buying decision Marketing Management Installation and Trial Research representative approval agreement signing • Post approval, the management begins negotiation meetings with • In standalone labs, the the supplier and once the deal is executed, the instrument is pathologists are usually the installed at the facility and staff is owners and the main decision given the training for handling it. makers whereas purchase is • A team of pathologists and lab made by a centralised technicians conduct the trial purchase department in case test to check for accuracy, of national chain laboratories efficiency, processing In some cases, especially for speed/volume and controls of closed systems like Roche or the equipment Abbott, the equipment is supplied free of cost as the company • The buyer does research to makes revenue through the analyse the current reagent repurchase agreements requirements of the market, existing/upcoming features, brand perception etc to move forward with the process • The representatives of different players approach the buyer to show their product portfolio Note(s): AMC – Annual Maintenance Contract; CMC – Comprehensive Maintenance Contract Source(s): Primary research, Secondary research,1Lattice analysis © 1lattice | 17 Purchase considerations - key considerations of GTM Accuracy, cost and quality of the product are some of the major factors affecting the purchase decision Accuracy Brand name Cost Financing options Processing time • While making the • The brand name of the • The cost of the product • Financing options like • Molecular testing purchase decision, manufacturer also has a should be in line with loan, deferred payment techniques are known accuracy of the reports huge impact on the current market options, equipment on for being quicker and given by the equipment purchase decision standards and paying lease etc makes it easy more efficient than is a major consideration potential of the buyer to make the purchase traditional techniques. of the buyer decision Processing volume Quality Service Terms & Conditions • Due to high patient load • Regulatory authority • Quick response and • Terms & conditions of and operational costs, approval is required to immediate redressal of the sale agreement high processing volume ensure the product grievances enhances should be favourable to is a common preference meets the standard client’s confidence and the buyer. This must among all kinds of requirements leads to a positive specify the warranty buyers word-of-mouth details, AMC and CMC marketing conditions etc Note(s): AMC- Annual maintenance contracts; CMC- Comprehensive maintenance contracts Source(s): Primary research, Secondary research, 1Lattice analysis © 1lattice | 18 What we do for Medical Device companies BRAND RECALL MARKET ASSESSMENT • Market sizing & overview • Potential of different brands • TAM & SAM forecast of current • Brand recall vs competition, products across customer types, end • Customer segmentation consumers, geography, hospital types, etc. • Replacement demand • Customer retention • Growth drivers and opportunities • Competitor pipeline and portfolio • Industry best practices assessment • Price benchmarking by TA CUSTOMER NPS • Competitive positioning of products • NPS score & referral rate • Conjoint analysis of features and pricing vs competition • Customer segments unsatisfied & risk to brand • Drivers for customer loyalty & NPS, VENDOR FEEDBACK DISTRIBUTORS / CHANNELS client vs competition • Vendor Feedback Survey & NPS • Digital technology play to improve NPS • Channel NPS • Vendor Performance Benchmarking and • Latent & unmet needs of customers • Split between online & offline etc. Consolidation • Gaps in customer experience vs • Channel margin structure vs competition • Vendor Identification, Assessment and • Geographical penetration vs competition Cost-Benchmarking • Incentives / schemes working well • Scoring against 1Lattice vendor bench- marking toolkit • Drivers / barriers to expansion • Cost components vs competition & indus- • Channel trading terms try standard © 1lattice | 19 Select experience: Medtech Product launch Value products Radiology equipment Value products Commercial due strategy for AWC services concept testing diligence on hemostats offering design products Developed product launch Performed need-based Perform ed conjoint Perform market Performed CDD for a segmentation to help analysis on multiple assessment of after-sales leading Indian plan for a leading Indian design offering of product and service services for radiology consumables player who consumables player who “value” products for a concepts for “value” equipment, conduct was looking to acquire a was looking to acquire a large global diagnostic products for a large global services feedback and company dealing with company dealing with equipment player diagnostic equipment benchmark it with hemostats advanced wound dressing player competitors products Medical supplies Contactless eCommerce Continuous medical Orthopedic centers platform monitoring features platform education Feature prioriti z ation for a Design pilot orthopedic Built an ecom merce International expansion Understand the CME need contactless monitoring center model for a leading platform for retailers of strategy for an online of healthcare providers product in the research orthopedic company a leading eye lens medical supplies' platform – doctors / surgeons, nurses, phase by performing interested to venture into manufacturer to enable to ME/SEA; build GPO / VPO paramedics, radiologists, MaxDiffanalysis for a large orthopedic centers online selling strategy to become etc. and design the overall global equipment player end-to-end supply chain CME offering partner of hospitals © 1lattice | 20 We’re here for you Let us know how can we meet your business requirement? Arindam Gupta Saloni Kumar Connect now EVP- Healthcare & Lifesciences BA - Healthcare & Lifesciences Vaishnav Kumar Rai E: arindam.gupta@1lattice.com E: saloni.kumar@1lattice.com Manager – Corporate Communications M: +91 995 819 9600 M: +91 9354136008 E: communications@1lattice.com M: +91 782 794 4925 Gurugram Bengaluru hello@1lattice.com New Delhi Mumbai www.1lattice.com Disclaimer: This material has been prepared by 1Lattice, which is the trade name of Lattice Technologies Private Limited (“1Lattice”, “we” or “our”) with the intent to showcase our capability and disseminate learnings to potential partners/clients. This material can be referred to by the readers on the internet but should be referenced to 1Lattice, if reused or adapted in any form, or medium and on any forum. The frameworks, approaches, tools, analysis and opinions are solely 1Lattice’s intellectual property and are a combination of the collection of the best data we could find publicly, and the 1Lattice team’s own experiences and observations. Any information provided herein is only for informational purposes and you are advised to perform an independent analysis of the same before making any decision based on such information. The information does not constitute any business advice or guidance and is to be construed as a general summary based upon the publicly available information and our interpretation of the same using our resources. For this material, we may have relied upon different sources of information which may be primary sources, publicly available information, and relevant information available with us. We make no representation or warranty, expressed or implied, that such information is accurate or complete, and nothing contained here can be construed as definitive predictions or forecasts. Before reading further, the Recipient expressly agrees that this might not address any and all risks and challenges facing the Recipient, its business, and the markets within which it operates, nor all possible market conditions. Any use of the information provided herein by the viewer shall be at the sole risk of the viewer and 1Lattice or its business partners, affiliates, agents, officers or employees shall not be liable for any unintended or adverse effect or outcome from the use of such information by the reader. 1Lattice does not have any duty to update or supplement any information in this document. 1Lattice shall not be responsible for any business or commercial loss sustained by any person who relies on any information provided herein. Any and all logos of companies used in the information provided herein have been published for information purposes only and 1Lattice does not hold any liability in connection therewith. 1Lattice We enable better decision making. Technology-backed business support that helps you ENABLE BETTER 500+ 30% annual engagements faster to outcomes DECISIONS Deep on-ground insights that you can act on 8 600+ practices years domain expertise 4 offices, deep experience across geographies – India, the USA, Europe, MEA, and SEA regions 130+ 98%+ team members accuracy One-ness of data and people networks to harness the collective power of data, network, and technology 100+ 2.5M towns & cities panel members Multi-faceted teams offering a stack of consulting, advisory, and research services 15+ 40:60 languages covered she/he ratio The team at appreciates your time and support THANK YOU Enabling Better Decisions. New Delhi Gurugram Mumbai Bengaluru Unit 5, Ground Floor, Tower A, 4th Floor, 112, First floor, 2734, Fourth floor, Uppal Plaza M6, District DLF Centre Court,DLF Workafella, AK Estate, HSR Layout, Sector 1, Centre, Jasola -110 025 Phase 5, Sector Goregaon West, 27th Main, 16th Cross, New Delhi, India 42,Gurugram-122002 Mumbai - 400 062 Bengaluru - 560 102 Haryana, India Maharashtra, India Karnataka, India Registered address: Unit 5, Ground Floor, Uppal Plaza M6, District Centre, Jasola, New Delhi -110025
